Novartis has developed a groundbreaking therapy that has the potential to significantly reduce the risk of heart attacks. This innovative treatment focuses on lowering low-density lipoprotein cholesterol (LDL-C), often referred to as “bad” cholesterol, which is a major contributor to heart disease.
The Importance of LDL-C Management
Maintaining healthy LDL-C levels is paramount for cardiovascular health. When LDL-C levels are elevated, it accumulates in the arteries, forming plaques that harden and narrow these vital blood vessels. This process, known as atherosclerosis, restricts blood flow to the heart, increasing the risk of heart attack and stroke.
Medical experts recommend maintaining LDL-C levels below 70 mg/dL to effectively remove accumulated plaque in the arteries. By achieving this target, individuals can significantly reduce their risk of experiencing a heart attack.
Introducing Inclisiran: A Revolutionary Cholesterol-Lowering Therapy
Inclisiran is a cutting-edge therapy developed by Novartis that offers a new approach to LDL-C management. This medication has demonstrated remarkable efficacy in clinical trials, showcasing its ability to significantly lower LDL-C levels.
One of the most notable advantages of Inclisiran is its dosing regimen. Patients only require two doses per year, making it a convenient and practical treatment option. This is in stark contrast to traditional statin therapy, which often involves daily medication.
Clinical studies have revealed that Inclisiran can reduce LDL-C levels by up to 52%. This substantial reduction in LDL-C translates into a significant decrease in the risk of cardiovascular events, especially for high-risk patients who find it challenging to control their cholesterol levels with conventional statin therapy.
Empowering Filipinos: The siRNA Roadshow
Recognizing the importance of raising awareness about LDL-C management and promoting heart-healthy lifestyles, Novartis Healthcare Philippines has launched an impactful campaign called “Turning Second Chances to Lifelong Victories: The siRNA Roadshow.”
This initiative involves collaboration with leading cardiologists who strive to empower Filipinos to take control of their heart health.
The campaign centers around educating individuals about the risks associated with uncontrolled LDL-C and providing them with the knowledge and tools to manage their cholesterol levels effectively.
By emphasizing the importance of regular checkups, healthy lifestyle choices, and adherence to prescribed medications, the siRNA Roadshow aims to create a nationwide movement towards better heart health.
Investing in Health: The Long-Term Benefits of LDL-C Control
Controlling LDL-C levels is not merely about preventing heart attacks; it is an investment in one’s overall health and well-being. By maintaining healthy cholesterol levels, individuals can reduce their risk of developing other serious health conditions, such as stroke, peripheral artery disease, and heart failure.
Moreover, managing LDL-C can enhance quality of life by reducing the likelihood of experiencing debilitating symptoms associated with cardiovascular disease. This allows individuals to lead active, fulfilling lives and enjoy more precious moments with loved ones.
Frequently Asked Questions about LDL-C and Inclisiran
What is LDL-C, and why is it called “bad” cholesterol?
LDL-C, or low-density lipoprotein cholesterol, is a type of fat-like substance that circulates in the blood. High levels of LDL-C can contribute to plaque buildup in the arteries, increasing the risk of heart attack and stroke. That’s why it’s often referred to as “bad” cholesterol.
What are the symptoms of high LDL-C?
High LDL-C usually doesn’t cause noticeable symptoms. That’s why regular cholesterol checks are crucial, especially if you have risk factors for heart disease.
How can I lower my LDL-C levels?
Lifestyle modifications, such as maintaining a healthy weight, engaging in regular exercise, and adopting a heart-healthy diet low in saturated and trans fats, can help lower LDL-C. In some cases, medications like statins or Inclisiran may be necessary.
How does Inclisiran work differently from statins?
Inclisiran belongs to a new class of drugs called small interfering RNA (siRNA) therapies. It works by targeting and silencing a specific protein in the liver responsible for producing LDL-C. Statins, on the other hand, inhibit an enzyme involved in cholesterol production.
What are the side effects of Inclisiran?
Like any medication, Inclisiran may cause side effects. Common side effects are generally mild and may include injection site reactions, headache, or fatigue.
Who is eligible for Inclisiran treatment?
Inclisiran is typically prescribed to individuals with high cholesterol who are at increased risk of heart attack or stroke and have not achieved their cholesterol goals with other therapies.
Conclusion
The introduction of Inclisiran marks a significant advancement in the fight against heart disease. Its effectiveness in dramatically lowering LDL-C, combined with its convenient dosing regimen, makes it a game-changer for high-risk individuals struggling to manage their cholesterol levels.
The “Turning Second Chances to Lifelong Victories: The siRNA Roadshow” campaign reflects Novartis Healthcare Philippines’ commitment to empowering Filipinos to prioritize their heart health. By raising awareness about the importance of LDL-C management, the initiative encourages individuals to take proactive steps towards a healthier future.
Controlling LDL-C is an investment in long-term health and well-being. By embracing healthy lifestyle choices and seeking appropriate medical advice, Filipinos can reduce their risk of heart disease and live longer, healthier lives.
Source: Malaya.com.ph